ICON

Company

ICON develops one asset, in phase 1 (ACI-19764 in cardiovascular risk). Mostly small molecule acting on NLRP3, NLRP3 inflammasome and inflammation.

1
Asset
Furthest stage: Phase 1; 0
Trials: 0
Signals

Pipeline

1

ACI-19764
Inhibits NLRP3 inflammasome activation to reduce downstream inflammatory cytokine release.
Phase 1, Small molecule, NLRP3, NLRP3 inflammasome, cardiovascular risk, obesity, Partner

Full company profiles: pipeline, trials, funding and people.

Subsidiaries

1

ICON Clinical Research
1 asset

In the full profile

Evidence behind the mechanisms3
Trials14
Signals1
Similar companies6